The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.
The FDA has expanded the indication for pitolisant to include treatment for cataplexy in pediatric patients aged 6 years and older, making it the only non-scheduled therapy approved for narcolepsy with or without cataplexy in both pediatric and adult populations. This approval enhances treatment options for managing excessive daytime sleepiness and cataplexy associated with narcolepsy.
Background
Narcolepsy is a rare neurological disorder affecting approximately 170,000 individuals in the US, characterized by excessive daytime sleepiness and cataplexy. The recent approval of pitolisant for pediatric patients marks a significant advancement in treatment options, as it is the only non-scheduled medication available for this condition. Pitolisant is a selective histamine 3 receptor antagonist and inverse agonist, believed to increase histamine release, promoting wakefulness. Understanding the implications of this approval is crucial for clinicians managing narcolepsy in diverse patient populations.
Data Highlights
No numerical data provided in the source material.
Key Findings
Pitolisant is now approved for treating excessive daytime sleepiness and cataplexy in patients aged 6 years and older.
The drug was initially approved in August 2019 for excessive daytime sleepiness in adults.
In October 2020, the indication was expanded to include cataplexy in adults.
Common adverse reactions in adults include insomnia, nausea, and anxiety, while in pediatric trials, headache and insomnia were most frequently reported.
Pitolisant is contraindicated in patients with known hypersensitivity or severe hepatic impairment.
The medication prolongs the QT interval and should be avoided in patients with known QT prolongation or a history of cardiac arrhythmias.
Clinical Implications
Clinicians should consider pitolisant as a treatment option for both pediatric and adult patients with narcolepsy, particularly for those experiencing cataplexy. It is essential to monitor patients for potential adverse reactions and contraindications, especially regarding cardiac health and QT prolongation.
Conclusion
The broadening of the pitolisant label represents a significant step forward in the management of narcolepsy, providing clinicians with a valuable tool for treating both pediatric and adult patients. Ongoing education and adherence to updated guidelines will be critical in optimizing patient outcomes.
Narrative review linked lower vitamin D levels to greater myopia risk and higher omega-3 intake to lower risk, though outdoor exposure may explain the vitamin D association.
